Zepbound is specifically indicated as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbid condition
Some people regain weight even after surgery
A molecule that fits perfectly into GLP-1 receptors might not activate GIP receptors effectively, and vice versa
Retatrutide is the first triple-agonist peptide to hit GLP-1, GIP, and glucagon receptors at the same time
"We are excited to share that the Zepbound single-dose vials are now here, further delivering on our promise to increase supply of Zepbound in the US," said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA
They promise the benefits of modern medicine without the needles or strict regulations